{"schema_version":"1","generated_at":"2026-11-02T14:17:50.443Z","data_as_of":null,"url":"https://www.findmykol.com/kol/nikolai-podoltsev","json_url":"https://www.findmykol.com/kol/nikolai-podoltsev/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"nikolai-podoltsev","name":"Nikolai Podoltsev","credential":"MD, PhD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"Yale Cancer Center","institution_url":"https://www.findmykol.com/institution/yale-school-of-medicine","city":"New Haven","state":"CT","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1891731667","orcid":"0000-0002-3657-778X","openalex":"A5015755664"},"summary":"Nikolai Podoltsev is a Hematology physician affiliated with Yale Cancer Center. OpenAlex indexes 321 publications with 6,353 citations (h-index 37).","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":321,"cited_by_count":6353,"h_index":37,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":16,"program_years":{"first":2021,"last":null},"rows_total":30,"shown":3,"withheld":27,"rows":[{"payer":"SOBI, INC","program_year":2025,"amount_usd":10444.53,"payment_count":7,"source_url":"https://openpaymentsdata.cms.gov/search?query=1891731667"},{"payer":"Takeda Pharmaceuticals U.S.A., Inc.","program_year":2025,"amount_usd":3676.29,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1891731667"},{"payer":"Amgen Inc.","program_year":2025,"amount_usd":2777.46,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1891731667"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1891731667","source":"payments"},"prescribing":{"data_year":2024,"areas_total":7,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":79.3,"classes_total":8,"classes":[{"class":"Kinase inhibitor","setting":"prescribed","share_pct":47.7,"drugs":[{"name":"Jakafi","share_pct":49.1},{"name":"Bosulif","share_pct":16.7},{"name":"Imatinib Mesylate","share_pct":14.9},{"name":"Ayvakit","share_pct":8.9},{"name":"Sprycel","share_pct":6.3},{"name":"Iclusig","share_pct":4.1}],"max_beneficiaries":null},{"class":"Antimetabolite","setting":"prescribed","share_pct":8.7,"drugs":[{"name":"Hydroxyurea","share_pct":100}],"max_beneficiaries":17}]},{"area":"Metabolism & gastrointestinal","share_pct":6.7,"classes_total":1,"classes":[{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":6.7,"drugs":[{"name":"Ondansetron Odt","share_pct":100}],"max_beneficiaries":19}]},{"area":"Blood & clotting","share_pct":4.4,"classes_total":2,"classes":[{"class":"Thrombopoietin Receptor Agonist","setting":"prescribed","share_pct":2.5,"drugs":[{"name":"Promacta","share_pct":100}],"max_beneficiaries":null},{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":2,"drugs":[{"name":"Eliquis","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML","year":2023,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.22.02721","status":"verified"},{"title":"A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML","year":2023,"journal":"Leukemia","source_url":"https://doi.org/10.1038/s41375-023-02073-x","status":"verified"},{"title":"Follow-up of patients with R/R <i>FLT3-</i>mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","year":2022,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2021011583","status":"verified"},{"title":"Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","year":2022,"journal":"Journal of the National Comprehensive Cancer Network","source_url":"https://doi.org/10.6004/jnccn.2022.0046","status":"verified"},{"title":"Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib","year":2022,"journal":"Blood Cancer Journal","source_url":"https://doi.org/10.1038/s41408-022-00677-7","status":"verified"}],"source":"works"},"contact":{"address_1":"333 CEDAR ST","address_2":"YALE UNIVERSITY SCHOOL OF MEDICINE, HEMATOLOGY DIVISION","city":"New Haven","state":"CT","zip":"065103206","phone":"203-200-4363","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1891731667","source":"identity"},"similar":[{"name":"Ian Krop","slug":"ian-krop","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ian-krop","json_url":"https://www.findmykol.com/kol/ian-krop/profile.json"},{"name":"Harriet Kluger","slug":"harriet-kluger","institution":"Yale Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/harriet-kluger","json_url":"https://www.findmykol.com/kol/harriet-kluger/profile.json"},{"name":"Stephanie Halene","slug":"stephanie-halene","institution":"Yale Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/stephanie-halene","json_url":"https://www.findmykol.com/kol/stephanie-halene/profile.json"},{"name":"John Kunstman","slug":"john-kunstman","institution":"Yale Cancer Center","specialty":"Surgical Oncology","url":"https://www.findmykol.com/kol/john-kunstman","json_url":"https://www.findmykol.com/kol/john-kunstman/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":27,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2013-01-11","collected_at":"2026-11-02T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}